Format

Send to

Choose Destination
Oncoimmunology. 2015 Apr 14;4(10):e1029705. eCollection 2015 Oct.

Genetics and immunology: reinvigorated.

Author information

1
Dept. of Medicine; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
2
Human Oncology and Pathogenesis Program; Memorial Sloan-Kettering Cancer Center ; New York, NY USA.
3
Division of Hematology/Oncology; New York Presbyterian/Columbia University Hospital ; New York, NY USA.

Abstract

Immune checkpoint blockade therapy is changing oncology by improving the outcome of patients with advanced malignancies. Our research has revealed the genetic features of tumors present in patients who initiate a successful antitumor immune response and derive clinical benefit from immune checkpoint blockade therapy versus non-responders.

KEYWORDS:

CTLA-4; PD-1; biomarkers; cancer; genomics; immunomonitoring; immunotherapy; mutation; new targets

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center